The Tri-Service General Hospital is a medical center in Neihu District, Taipei, Taiwan. It is the teaching hospital of the National Defense Medical Center.

During the past decade, Tri-Service General Hospital conducted 55 clinical trials. In the 10-year time frame, 55 clinical trials started and 12 clinical trials were completed, i.e. on average, 21.8% percent of trials that started reached the finish line to date. In the past 5 years, 30 clinical trials started and 7 clinical trials were completed. i.e. 23.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tri-Service General Hospital" #1 sponsor was "National Defense Medical Center, Taiwan" with 12 trials, followed by "Tri-Service General Hospital" with 11 trials sponsored, "Eli Lilly and Company" with 8 trials sponsored, "Loxo Oncology, Inc." with 3 trials sponsored and "National Health Research Institutes, Taiwan" with 3 trials sponsored. Other sponsors include 31 different institutions and companies that sponsored additional 36 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tri-Service General Hospital" #1 collaborator was "Tri-Service General Hospital" with 5 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator, "Orient Europharma Co., Ltd." with 2 trials as a collaborator, "ARMO BioSciences" with 1 trials as a collaborator and "AbbVie" with 1 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "Tri-Service General Hospital" are "Hyperuricemia" (3 trials), "Breast Cancer" (2 trials), "Coronary Artery Disease" (2 trials), "Glioblastoma" (2 trials) and "Hepatitis B, Chronic" (2 trials). Many other conditions were trialed in "Tri-Service General Hospital" in a lesser frequency.

Most popular intervention types in "Tri-Service General Hospital" are "Drug" (48 trials), "Biological" (7 trials), "Device" (7 trials), "Other" (6 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Abemaciclib" (3 trials), "Pembrolizumab" (2 trials), "heart rate variability biofeedback" (2 trials) and "1000 mL 0.9% sterile saline" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tri-Service General Hospital" are 71 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Tri-Service General Hospital". undefined are not yet recruiting, 18 are recruiting, 5 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 35 completed trials in Tri-Service General Hospital, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Tri-Service General Hospital, 5 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 8 trials, and there were also 18 trials that are defined as “Not Applicable".